|
|
| VGX
Pharmaceutical Announces Executive Promotions
|
| BLUE
BELL, P.A. – July 25, 2006– |
|
VGX Pharmaceuticals announced the promotion of Kevin
W. Rassas to Senior Vice President, Business Development and the promotion
of Robert Juba Jr. to Senior Director, Manufacturing and Quality.
“Kevin is providing excellent leadership in a variety of areas critical
to the development of the Company,” said Dr. Joseph Kim, a CEO and
President. “This promotion recognizes his valuable contribution
and I am confident that he will continue to play an important role in
the overall success of the Company.”
Mr. Rassas joined the Company in 2003 as Vice President. He has over 25
years of pharmaceutical industry experience, including senior level general
management responsibility at Searle and Wyeth. He has a strong strategic
and operational focus with a proven track record of delivering solid revenue
growth and bottom line results. Mr. Rassas has played a major role in
the integration of large and complex businesses and has instituted numerous
programs to improve operating efficiencies. His background includes significant
experience in International Operations P&L Management, Strategic Planning,
Business Development, Finance and Administration, New Product Introductions
and Joint Ventures. Mr. Rassas received a Bachelor of Arts in Economics
from the University of Notre Dame and his MBA in Finance from the Kellogg
School of Management at Northwestern University. At VGX, Mr. Rassas has
overseen the Company’s overall business development and licensing
efforts, including the in-licensing of VGX-1027.
Mr. Juba joined the Company in 2005 as Director. He has been responsible
for all of VGX’s global manufacturing activities for its clinical
and preclinical programs, including VGX-150, VGX-1027, and VGX-100. Mr.
Juba has more than 11 years of experience in the pharmaceutical industry,
mostly at Merck & Co. He has managed several contract manufacturing
and filling projects for developmental products (Vaccines for Rotavirus
and HIV-1), led pilot plant operations for research and clinical supply
manufacturing, and provided technical expertise for bacterial vaccine
manufacturing. He has extensive experience in managing cGMP processes
and operations. Mr. Juba holds both Bachelor's and Master's Degrees in
Chemical Engineering from the Massachusetts Institute of Technology.
“Rob provides a wealth of experience in leading a focused effort
to advance the Company’s manufacturing planning and capacity not
only for our on-going clinical studies but also future clinical projects
the Company is planning,” said Dr. Kim.
Cautionary
Factors That May Affect Future Results - Materials in this
Web site contain information that includes or is based upon forward-looking
statements within the meaning of the Securities Litigation Reform
Act of 1995. Forward-looking statements relate to expectations or
forecasts of future events. You can identify these statements by the
fact that they do not relate strictly to historical or current facts.
They use words such as "anticipate," "estimate,"
"expect," "project," "intend," "plan,"
"believe," and other words and terms of similar meaning
in connection with a discussion of potential future events, circumstances
or future operating or financial performance. In particular, these
include statements relating to future actions, prospective products
or product approvals, future performance or results of current and
anticipated products, sales efforts, expenses, the outcome of contingencies
such as legal proceedings, and financial results. Any or all of our
forward-looking statements here or in other publications may turn
out to be wrong. They can be affected by inaccurate assumptions or
by known or unknown risks and uncertainties. Many such factors will
be important in determining our actual future results. Consequently,
no forward-looking statement can be guaranteed, and forward-looking
statements may be adversely affected by factors, including general
market conditions, competitive product development, product availability,
current and future branded and generic competition, federal and state
regulations and legislation, manufacturing issues, timing of the elimination
of trade buying, patent positions, litigations and investigations.
Our actual results may vary materially, and there are no guarantees
about the performance or valuation of VGX stock. It is also important
to read the disclosure notice contained in many of the individual
VGX documents available on this Web site as many contain important
information on such cautionary factors as of the date of the individual
document. We undertake no obligation to correct or update any forward-looking
statements, whether as a result of new information, future events
or otherwise. You are advised, however, to consult any further disclosures
we make on related subjects in our reports. |
About
VGX Pharmaceuticals
VGX Pharmaceuticals is a leading biopharmaceutical company with strong product
candidates for the treatment of infectious diseases including HIV and hepatitis
C virus (HCV) as well as cancer and inflammatory diseases. The Company’s
clinical development programs include PICTOVIR™ for HIV infection
and VGX-410C for chronic HCV infection, which are currently in Phase II
clinical trials. In addition, a Phase I clinical trial will be initiated
in 2006 for the Company’s lead cancer drug compound, VGX-150 for the
treatment of Melanoma. Moreover, VGX Pharmaceuticals’ therapeutic
platform is designed to advance a strong and continual pipeline of additional
drug candidates into the clinic with VGX-100 for cancer therapy and VGX-1027
and VGX-750 for inflammatory diseases currently in development. The product
candidates and technology programs are protected by the Company’s
extensive global intellectual property portfolio. More information about
VGX can be found at www.vgxp.com.
Company Contact:
Kevin W. Rassas
Senior Vice President
Tel 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com
|
